ATAI Investor Presentation Deck

Depression Opportunity Overview Depression is a mood disorder that affects the thoughts and behavior of an individual, leading to psychological, physical, and social problems First onset depression (MDD) Persistent depression (MDD) Depression in numbers Treatment resistant depression (TRD) Treatment resistant depression (TRD) is diagnosed after two failed courses of antidepressants ~300m Global sufferers of depression 2nd Leading cause of disability worldwide (2019)² ~$300bn U.S. economic burden from adults with MDD (direct + indirect costs)³ (1) World Health Organization (2020) (2) World Health Organization - Disease Burden 2000-2019 (2020) (3) Greenberg et al., "The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)" (2021) (4) Al-Harbi et al., "Treatment-resistant depression: therapeutic trends, challenges, and future directions" (2012) URGENT NEED FOR INNOVATION -30% Up to 12 weeks -38% 7 Inadequate response rate A third of patients with depression respond inadequately or relapse with current treatments and are classified as "treatment resistant" 4 Slow onset of treatment effect Frontline SSRI treatments for depression have slow onset (4-12w)5 11 Long-term side effects Over a third of patients experience one or more side effects as a result of SSRI antidepressants FDA approvals since 2017 Only 7 new drugs approved by the FDA for depression since 2017, less than 6% relative to oncology (N=116)' (5) Tew et al., "Impact of prior treatment exposure on response to antidepressant treatment in late life" Am J Geriatr Psychiatry (2006) (6) Cascade et al., "Real-World Data on SSRI Antidepressant Side Effects Psychiatry MMC (2009) (7) GlobalData (as of 12.09.2022). Excludes generics and biosimilars

View entire presentation